Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

While first line targeted therapies are the current standard of care treatment for non-small cell lung cancer (NSCLC) with actionable mutations, the cancer cells inevitably acquire resistance to these agents over time. Immune check-point inhibitors (ICIs) have improved the outcomes of metastatic NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Seegobin, Karan, Majeed, Umair, Wiest, Nathaniel, Manochakian, Rami, Lou, Yanyan, Zhao, Yujie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671626/
https://www.ncbi.nlm.nih.gov/pubmed/34926258
http://dx.doi.org/10.3389/fonc.2021.750657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671626/
https://www.ncbi.nlm.nih.gov/pubmed/34926258
http://dx.doi.org/10.3389/fonc.2021.750657

Ejemplares similares